Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.
de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S. de Kruijff IE, et al. Cancers (Basel). 2018 May 5;10(5):134. doi: 10.3390/cancers10050134. Cancers (Basel). 2018. PMID: 29734758 Free PMC article.
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.
de Kruijff IE, Sieuwerts AM, Onstenk W, Kraan J, Smid M, Van MN, van der Vlugt-Daane M, Hoop EO, Mathijssen RHJ, Lolkema MP, de Wit R, Hamberg P, Meulenbeld HJ, Beeker A, Creemers GJ, Martens JWM, Sleijfer S. de Kruijff IE, et al. Cancers (Basel). 2019 Aug 20;11(8):1212. doi: 10.3390/cancers11081212. Cancers (Basel). 2019. PMID: 31434336 Free PMC article.
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
Verschoor N, Bos MK, de Kruijff IE, Van MN, Kraan J, Drooger JC, Zuetenhorst JM, Wilting SM, Sleijfer S, Jager A, Martens JWM. Verschoor N, et al. Among authors: de kruijff ie. Breast Cancer Res Treat. 2024 May;205(1):87-95. doi: 10.1007/s10549-023-07231-4. Epub 2024 Jan 31. Breast Cancer Res Treat. 2024. PMID: 38291268 Free PMC article. Clinical Trial.
Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
Beije N, de Kruijff IE, de Jong JJ, Klaver SO, de Vries P, Jacobs RAL, Somford DM, Te Slaa E, van der Heijden AG, Alfred Witjes J, Fossion LMCL, Boevé ER, van der Hoeven J, van Melick HHE, Wijburg CJ, Bickerstaffe H, Martens JWM, de Wit R, Kraan J, Sleijfer S, Boormans JL. Beije N, et al. Among authors: de kruijff ie. ESMO Open. 2022 Apr;7(2):100416. doi: 10.1016/j.esmoop.2022.100416. Epub 2022 Mar 3. ESMO Open. 2022. PMID: 35248823 Free PMC article.
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients.
de Kruijff IE, Sieuwerts AM, Beije N, Prager-van der Smissen WJC, Angus L, Beaufort CM, Van MN, Oomen-de Hoop E, Jager A, Hamberg P, de Jongh FE, Kraan J, Martens JWM, Sleijfer S. de Kruijff IE, et al. Front Oncol. 2021 Jun 25;11:697572. doi: 10.3389/fonc.2021.697572. eCollection 2021. Front Oncol. 2021. PMID: 34249756 Free PMC article.
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY. De Laere B, et al. Among authors: de kruijff ie. Clin Cancer Res. 2019 Mar 15;25(6):1766-1773. doi: 10.1158/1078-0432.CCR-18-1943. Epub 2018 Sep 12. Clin Cancer Res. 2019. PMID: 30209161 Free PMC article. Clinical Trial.